secwatch.observer — SEC 8-K summary
======================================

Issuer:     Minerva Neurosciences, Inc. (NERV)
CIK:        0001598646
Form:       8-K
Filed at:   2026-08-07T11:13:34+00:00
Accession:  0001193125-26-339147
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Minerva Q2 GAAP net income $17.5M on $27.6M non-cash warrant gain; adjusted loss $7.8M
--------------------------------------------------------------------------------

- Q2 2026 GAAP net income of $17.5M ($0.36 basic, $(0.14) diluted) vs net loss of $3.3M year-ago; driven by $27.6M non-cash warrant gain.
- Adjusted non-GAAP net loss of $7.8M vs $3.0M year-ago; H1 adjusted loss $15.1M vs $6.4M. Cash $75.4M, down from $82.4M at Dec 31, 2025.
- R&D expense $7.2M (Q2) vs $1.3M; G&A $3.5M vs $2.1M, up on C19 trial costs, professional fees and compensation.
- Phase 3 C19 roluperidone trial (380 patients, ~40 sites) on track; Phase A topline expected 2H 2027, Phase B 2H 2028.
- Scientific Advisory Board expanded to 11 members, adding Correll, Leucht and Sand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/0001193125-26-339147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/d22348d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-339147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer